Recurrent Respiratory Papillomatosis: Update 2021 (AMW)
2021 AAO-HNSF Annual Meeting & OTO Experience
Recurrent Respiratory Papillomatosis continues to be a vexing disease affecting children and adults. Caused by human papillomavirus (HPV) subtypes 6 and 11, we have the potential to significantly reduce the future burden of this disease through comprehensive HPV vaccination of children. Ongoing studies in the US, Canada and Australia will be presented showing reduction in new cases with increased uptake of the vaccine. Efforts to expand labeling to cover prevention of Head and Neck cancer (successful) and RRP (ongoing) will be discussed. Strategies to improve uptake of the HPV-9 vaccine, cost-effective approaches to partner with industry and the public, and techniques for speaking to your patients regarding vaccination will be undertaken. Research involving reducing dosing requirements and the results of vaccination in resource-limited environments will be presented. Updates from the activities of the RRP Task Force and highlights from the International Papillomavirus Conference 2020 will be discussed.
Credits
CME:1.0, MOC:1.0